ranimustine ranimustine ranimustine (inn, marketed under the tradename cymerin; also known as mcnu) is a nitrosourea alkylating agent approved in japan for the treatment of chronic myelogenous leukemia and polycythemia vera. ranimustineclinical datatrade namescymerinother names1-(2-chloroethyl)-1-nitroso-3-(methyl)ureaahfs/drugs.cominternational drug namesroutes ofadministrationivatc codel01ad07 (who) legal statuslegal status in general: ℞ (prescription only) identifiers iupac name methyl 6-(amino)-6-deoxy-α-d-glucopyranoside cas number58994-96-0 ypubchem cid71741chemspider64785uniiryh2t97j77chemical and physical dataformulac10h18cln3o7molar mass327.72 g·mol−13d model (jsmol)interactive image smiles co1((((o1)cnc(=o)n(cccl)n=o)o)o)o inchi inchi=1s/c10h18cln3o7/c1-20-9-8(17)7(16)6(15)5(21-9)4-12-10(18)14(13-19)3-2-11/h5-9,15-17h,2-4h2,1h3,(h,12,18)/t5-,6-,7+,8-,9+/m1/s1key:ahhfeznoxozzqa-zebdfxrssa-n (verify) it has never been filed for fda evaluation in the united states, where it is not marketed.